BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36219586)

  • 21. Chronic graft-versus-host disease in pediatric patients: Differences and challenges.
    Haroun E; Agrawal K; Leibovitch J; Kassab J; Zoghbi M; Dutta D; Lim SH
    Blood Rev; 2023 Jul; 60():101054. PubMed ID: 36805299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and Prognostic Biomarkers for Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Kalariya N; Bowe C; Dains JE
    Oncol Nurs Forum; 2020 Mar; 47(2):E35-E43. PubMed ID: 32078615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
    Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
    Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation.
    Nyilas S; Baumeler L; Tamm M; Halter JP; Savic S; Korten I; Meyer A; Singer F; Passweg JR; Latzin P; Stolz D
    Chest; 2018 Jul; 154(1):157-168. PubMed ID: 29275133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
    Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
    Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
    Zeiser R
    J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
    [No Abstract]   [Full Text] [Related]  

  • 28. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
    Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
    Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistopathology of oral mucosal chronic graft-versus-host disease severity and duration.
    Tollemar V; Ström J; Tudzarovski N; Häbel H; Legert KG; Heymann R; Warfvinge G; Le Blanc K; Sugars RV
    Oral Dis; 2023 Nov; 29(8):3346-3359. PubMed ID: 35796584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
    Kim DDH; Popradi G; Lepic K; Paulson K; Allan D; Nampoothiri RV; Lachance S; Deotare U; White J; Elemary M; Jamani K; Fraga C; Lemieux C; Novitzky-Basso I; Law AD; Kumar R; Walker I; Schultz KR;
    Curr Oncol; 2024 Mar; 31(3):1426-1444. PubMed ID: 38534941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple Breath Washout Testing to Identify Pulmonary Chronic Graft Versus Host Disease in Children After Hematopoietic Stem Cell Transplantation.
    Rayment JH; Sandoval RA; Roden JP; Schultz KR
    Transplant Cell Ther; 2022 Jun; 28(6):328.e1-328.e7. PubMed ID: 35139399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.
    Diep PP; Rueegg CS; Burman MM; Brinch L; Bø K; Fosså K; Landrø L; Loge JH; Lund MB; Massey RJ; Myrdal OH; Pathak M; Rimstad L; Tanem KE; Tjønnfjord GE; Aaløkken TM; Ruud E
    J Adolesc Young Adult Oncol; 2023 Feb; 12(1):66-75. PubMed ID: 35544321
    [No Abstract]   [Full Text] [Related]  

  • 33. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
    Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
    Front Immunol; 2020; 11():575492. PubMed ID: 33193367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
    Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
    Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic gvhd dictionary-eurograft cost action initiative consensus report.
    Zelić Kerep A; Olivieri A; Schoemans H; Lawitschka A; Halter J; Pulanic D; Dickinson A; Greinix HT; Pavletic SZ; Schultz KR; Lee SJ; Wolff D
    Bone Marrow Transplant; 2023 Jan; 58(1):68-71. PubMed ID: 36229646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.
    Goklemez S; Im AP; Cao L; Pirsl F; Steinberg SM; Curtis LM; Mitchell SA; Cowen EW; Baruffaldi J; Rose J; Mays J; Ostojic A; Holtzman NG; Hakim FT; Pavletic SZ
    Am J Hematol; 2020 Apr; 95(4):387-394. PubMed ID: 31903638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.
    Greinix HT; Kuzmina Z; Weigl R; Körmoczi U; Rottal A; Wolff D; Kralj M; Kalhs P; Mitterbauer M; Rabitsch W; Edinger M; Holler E; Pickl WF
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):250-8. PubMed ID: 25460358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease.
    DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S
    Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.